Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CymaBay Therapeutics, Inc.CBAY · Entity 92768 | Director | January 29, 2019 | January 31, 2019 |
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Chief Commercial Officer | June 04, 2018 | June 06, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CymaBay Therapeutics, Inc.
Report date January 29, 2019 · Filed January 31, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.43 · Expires 2029-01-28 | Direct | 27,705 |
Reported balance
After 2019-01-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-29 · Grant · Acquired 27,705 · Balance 27,705 F1: The option vests as to 1/12 of the underlying shares monthly from January 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 1/12 of the underlying shares monthly from January 1, 2019.
Pacira BioSciences, Inc.
Report date June 04, 2018 · Filed June 06, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,088 |
Reported balance
After 2018-06-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-06-04 · Sale · Disposed 373 · Balance 5,088 F1: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2: Includes 339 and 258 shares of common stock acquired under the issuer's employee stock purchase plan in June 2017 and December 2017, respectively. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.
F2: Includes 339 and 258 shares of common stock acquired under the issuer's employee stock purchase plan in June 2017 and December 2017, respectively.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 29, 2019 Filed Jan 31, 2019 17:23 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 27,705 | $0.00 Strike: $8.43 | $0.00 |
DisclosureSEC source: 0001333277-19-000024 · edgar.xml · derivative · entry 1 Weiland Robert J. · CIK 0001670648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,705 Underlying: Common Stock · 27,705 shares Expires 2029-01-28 F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from January 1, 2019. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 20:11 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 373 | $33.02 | $12,316.46 |
DisclosureSEC source: 0001209191-18-036185 · doc4.xml · nonDerivative · entry 1 Weiland Robert J. · CIK 0001670648 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,088 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes 339 and 258 shares of common stock acquired under the issuer's employee stock purchase plan in June 2017 and December 2017, respectively. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 17:46 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $11.69 | $0.00 |
DisclosureSEC source: 0001333277-18-000032 · edgar.xml · derivative · entry 1 Weiland Robert J. · CIK 0001670648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly beginning January 1, 2018. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 09:39 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $7.47 | $0.00 |
DisclosureSEC source: 0001209191-17-053902 · doc4.xml · derivative · entry 1 Weiland Robert J. · CIK 0001670648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-09-21 F1 · derivative.exercise_date: The shares subject to the option shall vest in 12 equal monthly installments commencing on June 1, 2017, subject to the Reporting Person's continuous service to the Issuer as of each such date. The option allows for early exercise by the Reporting Person. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 14:35 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001042074-17-000013 · primary_doc.xml · derivative · entry 1 Weiland Robert J. · CIK 0001670648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-27 F1 · derivative.exercise_date: The shares subject to the option shall vest in 12 equal monthly installments commencing on June 1, 2017. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 20:08 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $44.20 | $0.00 |
DisclosureSEC source: 0001209191-17-040685 · doc4.xml · derivative · entry 2 Weiland Robert J. · CIK 0001670648 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2027-06-14 F3 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 20:08 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040685 · doc4.xml · nonDerivative · entry 1 Weiland Robert J. · CIK 0001670648 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,864 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2018, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. F2 · balance_after: Includes 364 shares of common stock acquired under the issuer's employee stock purchase plan in December 2016. Read SEC document |
| January 19, 2017 Filed Jan 23, 2017 18:33 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001179110-17-001194 · edgar.xml · derivative · entry 1 Weiland Robert J. · CIK 0001670648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-01-18 F1 · derivative.exercise_date: The option vests in three annual installments from the vesting start date of January 19, 2017. Read SEC document |
| December 07, 2016 Filed Dec 9, 2016 20:27 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $32.35 | $0.00 |
DisclosureSEC source: 0001209191-16-154560 · doc4.xml · derivative · entry 1 Weiland Robert J. · CIK 0001670648 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2026-12-07 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.